LUPIN soars 13% on Wednesday, closes at NEW HIGH; Kotak upgrades the stock to BUY with revised Fair Value of Rs 1180
Kotak Institutional Equities says that Lupin is a buying opportunity for the investors and believes scale-up concerns on albuterol post supply disruptions and Sandoz entry are minor. Apart from albuterol, Lupin has multiple growth drivers in place over the medium term including progress on other inhalation assets, filing of biosimilars in the US and potential resolution of warning letters in 2HFY22
Lupin has also made advancement on the biosimilars front with partner Viatris launching biosimilar Enbrel in multiple EU countries: Reuters